Prempro Low(er) Clears FDA: .3 mg/1.5 mg Is Start Dose For Osteoporosis
Executive Summary
Wyeth's Prempro osteoporosis prevention treatment should begin with .3 mg conjugated estrogens/1.5 mg medroxyprogesterone following FDA approval of the lowest dose of the hormone therapy June 4
You may also be interested in...
Wyeth Prempro DTC
Wyeth expects to have DTC advertisements within the next several months to promote a lower dose of its hormone replacement therapy Prempro (.45 mg conjugated estrogens/1.5 mg medroxyprogesterone), which was launched July 1 after gaining FDA approval March 12 (1"The Pink Sheet" March 17, 2003, p. 4). Prempro .45 mg/1.5 mg is the middle dosing option in the Prempro franchise following the approval of the Prempro .3 mg/1.5 mg dose June 4 (2"The Pink Sheet" June 16, 2003, p. 35)...
Wyeth Prempro DTC
Wyeth expects to have DTC advertisements within the next several months to promote a lower dose of its hormone replacement therapy Prempro (.45 mg conjugated estrogens/1.5 mg medroxyprogesterone), which was launched July 1 after gaining FDA approval March 12 (1"The Pink Sheet" March 17, 2003, p. 4). Prempro .45 mg/1.5 mg is the middle dosing option in the Prempro franchise following the approval of the Prempro .3 mg/1.5 mg dose June 4 (2"The Pink Sheet" June 16, 2003, p. 35)...
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo